Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium  Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 28, 343-347, February 1, 1968]
© 1968 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Adamson, R. H.
Right arrow Articles by Oliverio, V. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Adamson, R. H.
Right arrow Articles by Oliverio, V. T.

Antitumor Activity and Some Pharmacologic Properties of Anthramycin Methyl Ether1

Richard H. Adamson, Larry G. Hart, Vincent T. DeVita and Vincent T. Oliverio

Laboratory of Chemical Pharmacology and Medicine Branch, National Cancer Institute, NIH, Bethesda, Maryland 20014

The antitumor antibiotic, anthramycin methyl ether (AME), was shown to be active in increasing survival time in mice bearing various experimental leukemias. Like actinomycin D, it was active against P388 but inactive against P388/38280. AME also was active against the plasma cell tumor LCP, while having no activity against the plasma cell tumor YPC-1. AME had an ID50 of 0.02 µg/ml against L1210 cells in tissue culture.

The effects of AME were studied on other pharmacologic parameters. Hexobarbital sleeping times were doubled in mice receiving daily injections of AME for 4 days, while single injections at times varying from 30 minutes to 4 hours prior to hexobarbital had no effect on sleeping time. AME did not affect the blood pressure, respiration, or EKG in anesthetized dogs, nor did it alter the blood pressure responses to various autonomic stimulants.

AME markedly inhibited uptake of tritiated uridine in both L1210 and P388 leukemic cells in vivo. AME also interfered with uptake of tritiated thymidine by L1210 cells. Spectral studies indicated that the ultraviolet absorption maximum of AME was shifted to longer wave lengths following interaction with DNA, but deoxyguanosine had no effect on the absorption maximum of AME. The anthranilic acid moiety did not form complexes with DNA or deoxyguanosine nor did it have cytotoxic effects in tissue culture in doses up to 1000 times that of the ID50 for AME.

1 A preliminary report of this study was presented at the Federation of American Societies for Experimental Biology, Chicago, Illinois, 1967.

Received 7/21/67. Accepted 10/19/67.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1968 by the American Association for Cancer Research.